Upregulation of TRAIL expression on human T lymphocytes by interferon β and glatiramer acetate

Multiple Sclerosis

Volumn 11, Issue 6, 2005, Pages 652-657

  Arbour, N ^a   Rastikerdar, E ^a   McCrea, E ^a   Lapierre, Y ^a   Dorr J ^b   Bar Or, A ^a   Antel, Jack P ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Neuroscience Research Center   (Germany)

Author keywords

Flow cytometry; Glatiramer acetate; Interferon type I; Multiple sclerosis; T lymphocytes; TRAIL

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CD3 ANTIGEN; GLATIRAMER; INTERFERON BETA SERINE; INTERFERON RECEPTOR; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; BLOOD SAMPLING; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG DOSE REGIMEN; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE SCLEROSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; T LYMPHOCYTE; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD3; APOPTOSIS REGULATORY PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; INTERFERON-BETA; MEMBRANE GLYCOPROTEINS; MULTIPLE SCLEROSIS; PEPTIDES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 28044463388     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458505ms1222oa     Document Type: Article

References (28)

1. Wendling U, Walczak H, Dorr J, Jaboci C, Weller M, Krammer PH et al. Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells. Cell Death Differ 2000; 7: 637-44.
2. Mirandola P, Ponti C, Gobbi G, Sponzilli I, Vaccarezza M, Cocco L et al. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood 2004; 104: 2418-24.
3. Lum JJ, Pilon AA, Sanchez-Dardon J, Phenix BN, Kim JE, Mihowich J et al. Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l. J Virol 2001; 75: 11128-36.
4. Herbeuval JP, Boasso A, Grivel JC, Hardy AW, Anderson SA, Dolan MJ et al. TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood 2004; 105: 2458-64.
5. Lunemann JD, Waiczies S, Ehrlich S, Wendling U, Seeger B, Kamradt T et al. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol 2002; 168: 4881-88.
6. Hilliard B, Wilmen A, Seidel C, Liu TS, Goke R, Chen Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J Immunol 2001; 166: 1314-19.
7. Dorr J, Bachmann I, Waiczies S, Aktas O, Walczak H, Krammer PH et al. Lack of tumor necrosis factor-related apoptosis-inducing ligand but presence of its receptors in the human brain. J Neurosci 2002; 22: RC209.
8. Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, Wendling U et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 2000; 356: 827-28.
9. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999; 189: 1451-60.
10. Fiumara P, Younes A. CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies. Br J Haematol 2001; 113: 265-74.
11. Flugel A, Berkowicz T, Ritter T, Labeur M, Jenne DE, Li Z et al. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 2001; 14: 547-60.
12. Huang WX, Huang MP, Gomes MA, Hillert J. Apoptosis mediators fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS. Neurology 2000; 55: 928-34.
13. Prat A, Weinrib L, Becher B, Poirier J, Duquette P, Couture R et al. Bradykinin B1 receptor expression and function on T lymphocytes in active multiple sclerosis. Neurology 1999; 53: 2087-92.
14. Paz A, Fiszer U, Zaborski J, Korlak J, Czlonkowski A, Czlonkowska A. Phenotyping analysis of peripheral blood leukocytes in patients with multiple sclerosis. Eur J Neurol 1999; 6: 347-52.
15. Kaplan MJ, Lewis EE, Shelden EA, Somers E, Pavlic R, McCune WJ et al. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 2002; 169: 6020-?9.
16. Wandinger KP, Lunemann JD, Wengert O, Bellmann-Strobl J, Aktas O, Weber A et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003; 361: 2036-43.
17. Qin Y, Zhang DQ, Prat A, Pouly S, Antel J. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. J Neuroimmunol 2000; 108: 201-6.
18. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000; 105: 967-76.
19. Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998; 92: 113-21.
20. Kim H, Antel J, Duquette P, Alleva D, Conlon P, Bar-Or A. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clin Immunol 2002; 104: 105.
21. Ehrlich S, Infante-Duarte C, Seeger B, Zipp F. Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes. Cytokine 2003; 24: 244-53.
22. Kim HJ, Ifergan I, Antel JP, Seguin R, Duddy M, Lapierre Y et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004; 172: 7144-53.
23. Khan OA, Xia Q, Bever CT Jr, Johnson KP, Panitch HS, Dhib-Jalbut SS. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology 1996; 46: 1639-43.
24. Sriram U, Barcellos LF, Villoslada P, Rio J, Baranzini SE, Caillier S et al. Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immunol 2003; 4: 147-52.
25. Zang Y, Hong J, Robinson R, Li S, Rivera VM, Zhang JZ. Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis. J Neuroimmunol 2003; 137: 144-53.
26. Mackay F, Kalled SL. TNF tigands and receptors in autoimmunity: an update. Curr Opin Immunol 2002; 14: 783-90.
27. Bertolotto A, Gilli F, Sala A, Audano L, Castello A, Magliola U et al. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 2001; 256: 141-52.
28. Calabresi PA, Stone LA, Bash CN, Frank JA, McFarland HF. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 1997; 48: 1446-48.